
Switching from tenofovir disoproxil fumarate (TDF)‐ to tenofovir alafenamide (TAF)‐containing antiretroviral therapy may negatively influence weight, cholesterol, and atherosclerotic cardiovascular disease risk. However, the extent of these changes and their association with TAF remains unclear. Despite observing significant unadjusted metabolic changes after switching to TAF, only changes in cholesterol were associated with TAF and were different from expected modifications in time‐trend adjusted models.
Like
Save
Share